{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=SC&page=91", "query": { "intervention": "SC", "page": 91 }, "page_size": 10 }, "pagination": { "page": 91, "page_size": 10, "total_count": 3868, "total_pages": 387, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=SC&page=92&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=SC&page=90&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-08T07:01:01.600Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04419649", "title": "A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Myelodysplastic Syndromes", "Cytopenia" ], "interventions": [ { "name": "Elritercept", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Takeda", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 210, "start_date": "2020-08-19", "completion_date": "2031-10-30", "has_results": false, "last_update_posted_date": "2026-10-19", "last_synced_at": "2026-11-08T07:01:01.600Z", "location_count": 11, "location_summary": "Hot Springs, Arkansas • Duarte, California • Miami, Florida + 8 more", "locations": [ { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Duarte", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04419649" }, { "nct_id": "NCT02009449", "title": "A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Melanoma", "Prostate Cancer", "Ovarian Cancer", "Renal Cell Carcinoma", "Colorectal Carcinoma", "Pancreatic Carcinoma", "Non-small Cell Lung Carcinoma", "Solid Tumors", "Breast Cancer" ], "interventions": [ { "name": "Pegilodecakin", "type": "DRUG" }, { "name": "Paclitaxel or Docetaxel and Carboplatin or Cisplatin", "type": "DRUG" }, { "name": "FOLFOX (Oxaliplatin/Leucovorin/5-Fluorouracil)", "type": "DRUG" }, { "name": "gemcitabine/nab-paclitaxel", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Pazopanib", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "nivolumab", "type": "DRUG" }, { "name": "Gemcitabine/carboplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 353, "start_date": "2013-11-15", "completion_date": "2023-07-22", "has_results": true, "last_update_posted_date": "2026-07-09", "last_synced_at": "2026-11-08T07:01:01.600Z", "location_count": 10, "location_summary": "Los Angeles, California • San Francisco, California • Denver, Colorado + 7 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02009449" }, { "nct_id": "NCT04383743", "title": "Pembrolizumab and Combination Chemotherapy Before Surgery for the Treatment of Muscle-Invasive Bladder Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Stage II Bladder Cancer AJCC v8", "Stage IIIA Bladder Cancer AJCC v8", "Muscle Invasive Bladder Carcinoma" ], "interventions": [ { "name": "Cisplatin", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Pegfilgrastim", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Radical Cystectomy", "type": "PROCEDURE" }, { "name": "Vinblastine Sulfate", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "PROCEDURE" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 17, "start_date": "2020-11-24", "completion_date": "2025-03-04", "has_results": true, "last_update_posted_date": "2025-09-18", "last_synced_at": "2026-11-08T07:01:01.600Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT04383743" }, { "nct_id": "NCT00701298", "title": "Decitabine With or Without Interferon Alfa-2b in Treating Patients With Unresectable or Metastatic Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "peginterferon alfa-2b", "type": "BIOLOGICAL" }, { "name": "decitabine", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2009-04", "completion_date": null, "has_results": false, "last_update_posted_date": "2014-02-24", "last_synced_at": "2026-11-08T07:01:01.600Z", "location_count": 1, "location_summary": "Las Vegas, Nevada", "locations": [ { "city": "Las Vegas", "state": "Nevada" } ], "official_url": "https://clinicaltrials.gov/study/NCT00701298" }, { "nct_id": "NCT03576963", "title": "Guadecitabine and Nivolumab in Treating Refractory Metastatic Colorectal Cancer", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Colorectal Adenocarcinoma", "CpG Island Methylator Phenotype", "Metastatic Microsatellite Stable Colorectal Carcinoma", "Refractory Colorectal Carcinoma", "Stage IV Colorectal Cancer AJCC v8", "Stage IVA Colorectal Cancer AJCC v8", "Stage IVB Colorectal Cancer AJCC v8", "Stage IVC Colorectal Cancer AJCC v8" ], "interventions": [ { "name": "Guadecitabine", "type": "DRUG" }, { "name": "Nivolumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "University of Southern California", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2020-01-30", "completion_date": "2023-01-30", "has_results": false, "last_update_posted_date": "2021-04-05", "last_synced_at": "2026-11-08T07:01:01.600Z", "location_count": 2, "location_summary": "Los Angeles, California • Newport Beach, California", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03576963" }, { "nct_id": "NCT07860021", "title": "VYVGART (Hytrulo) in Patients With Stiff Person Syndrome (SPS)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Stiff Person Syndrome" ], "interventions": [ { "name": "VYVGART Hytrulo", "type": "DRUG" }, { "name": "Hytrulo-placebo (consisting of Hyaluronidase)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Thomas Jefferson University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "25 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "25 Years to 80 Years" }, "enrollment_count": 26, "start_date": "2026-09-30", "completion_date": "2028-07-31", "has_results": false, "last_update_posted_date": "2026-10-06", "last_synced_at": "2026-11-08T07:01:01.600Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT07860021" }, { "nct_id": "NCT01972152", "title": "Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of G-Pen(TM) (Glucagon Injection) to Treat Severe Hypoglycemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hypoglycemia" ], "interventions": [ { "name": "G-Pen(TM) 1 mg", "type": "DRUG" }, { "name": "Lilly Glucagon(TM) 1 mg", "type": "DRUG" }, { "name": "G-Pen(TM) 0.5 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Xeris Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 30, "start_date": "2013-10", "completion_date": "2014-02", "has_results": true, "last_update_posted_date": "2016-02-03", "last_synced_at": "2026-11-08T07:01:01.600Z", "location_count": 1, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01972152" }, { "nct_id": "NCT03593915", "title": "A Phase 1b/2 Study of Alvocidib Plus Decitabine or Azacitidine in Patients With MDS", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Myelodysplastic Syndromes (MDS)" ], "interventions": [ { "name": "Alvocidib Plus Decitabine (during dose escalation only) or Azacitidine", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "COMBINATION_PRODUCT" ], "sponsor": "Sumitomo Pharma America, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2018-08-29", "completion_date": "2021-08-16", "has_results": true, "last_update_posted_date": "2023-11-09", "last_synced_at": "2026-11-08T07:01:01.600Z", "location_count": 12, "location_summary": "Chicago, Illinois • Iowa City, Iowa • Baltimore, Maryland + 9 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "New York", "state": "New York" }, { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03593915" }, { "nct_id": "NCT04255433", "title": "A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Type 2 Diabetes Mellitus" ], "interventions": [ { "name": "Tirzepatide", "type": "DRUG" }, { "name": "Dulaglutide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 13299, "start_date": "2020-05-29", "completion_date": "2025-06-12", "has_results": true, "last_update_posted_date": "2026-07-08", "last_synced_at": "2026-11-08T07:01:01.600Z", "location_count": 121, "location_summary": "Birmingham, Alabama • Concord, California • Covina, California + 106 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Concord", "state": "California" }, { "city": "Covina", "state": "California" }, { "city": "Escondido", "state": "California" }, { "city": "Fresno", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04255433" }, { "nct_id": "NCT02043847", "title": "TMI With HD Mel in ASCT for R/R Multiple Myeloma (BMT-03)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Myeloma, Relapsed", "Multiple Myeloma, Refractory to Standard Treatment" ], "interventions": [ { "name": "Total Marrow Irradiation", "type": "RADIATION" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Filgrastim (G-CSF)", "type": "DRUG" }, { "name": "Autologous transplant", "type": "PROCEDURE" } ], "intervention_types": [ "RADIATION", "DRUG", "PROCEDURE" ], "sponsor": "University of Illinois Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 12, "start_date": "2014-01-14", "completion_date": "2016-09-14", "has_results": true, "last_update_posted_date": "2024-11-13", "last_synced_at": "2026-11-08T07:01:01.600Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02043847" } ] }